Published in Hepatology on June 01, 2016
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med (2017) 0.96
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ΔNp63-miR-181a-Sirt1 pathway. J Leukoc Biol (2016) 0.75
Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List. Hepatology (2016) 0.75
SMAD about HCV cell entry and pathogenesis of liver disease. Gastroenterology (2016) 0.75
Genomic variants link to hepatitis C racial disparities. Oncotarget (2017) 0.75
Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation. Dig Dis Sci (2017) 0.75
Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthc (Amst) (2016) 0.75
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Hepatocellular carcinoma: recent trends in the United States. Gastroenterology (2004) 5.90
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 3.65
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med (2014) 3.50
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
Clinical practice. Chronic hepatitis C infection. N Engl J Med (2011) 2.54
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (2011) 1.81
The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol (2008) 1.77
Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol (2004) 1.68
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med (2015) 1.61
Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant (2010) 1.47
Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (2015) 1.44
Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis (2014) 1.43
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol (2014) 1.02
The impact and evolution of Medicare Part D. N Engl J Med (2014) 1.02
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Editorial commentary: Hepatitis C virus and the infectious disease physician: a perfect match. Clin Infect Dis (2012) 0.86
Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol (2015) 0.79
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer (2014) 0.81
Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology (2017) 0.75
Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study. Hepatology (2017) 0.75
Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period? Hepatology (2017) 0.75
Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol (2022) 0.75